<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20123" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Crigler-Najjar Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bhandari</surname>
            <given-names>Jenish</given-names>
          </name>
          <aff>Punjab Medical College/University of Health Scienes</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Thada</surname>
            <given-names>Pawan K.</given-names>
          </name>
          <aff>Punjab Medical College/University of Health Sciences</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shah</surname>
            <given-names>Manan</given-names>
          </name>
          <aff>Rutgers University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yadav</surname>
            <given-names>Deepak</given-names>
          </name>
          <aff>MountainView Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jenish Bhandari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pawan Thada declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manan Shah declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Deepak Yadav declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20123.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Crigler-Najjar syndrome is a&#x000a0;congenital autosomal recessive inherited disorder that leads to nonhemolytic jaundice. This syndrome is caused by an absence (CN1) or profoundly decreased level (CN2) of the enzyme UDP-glucuronosyltransferase due to a genetic defect in the <italic toggle="yes">UGT1A1</italic> gene. This condition results in hyperbilirubinemia that may present soon after birth. Severe forms of this disease can cause hyperbilirubinemia, which can potentially cause irreversible brain damage. Hence, prompt diagnosis and treatment are of utmost importance. This activity reviews the evaluation and management of Crigler-Najjar syndrome. This activity also highlights the interprofessional team's role in caring for newborns with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify Crigler-Najjar syndrome early in newborns presenting with persistent severe hyperbilirubinemia to facilitate prompt diagnosis and intervention.</p></list-item><list-item><p>Screen newborns for risk factors associated with the syndrome, such as family history, to ensure timely detection.</p></list-item><list-item><p>Apply appropriate therapeutic interventions, including phototherapy and liver transplantation, based on the identified type and severity of Crigler-Najjar syndrome.</p></list-item><list-item><p>Collaborate with a multidisciplinary team, including genetic counselors, pediatric neurologists, and surgeons, to ensure comprehensive and coordinated care.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20123&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20123">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20123.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Crigler-Najjar syndrome is a rare autosomal recessive disorder causing hyperbilirubinemia in newborns. Bilirubin metabolism involves the uptake of bilirubin from circulation, intracellular storage, conjugation with glucuronic acid, and excretion into bile. Abnormalities in any of these processes lead to hyperbilirubinemia. Crigler-Najjar syndrome is characterized by the absence or decreased activity of UDP-glucuronosyltransferase (UGT), an enzyme required for glucuronidation of unconjugated bilirubin in the liver.&#x000a0;This deficiency is a significant cause of congenital nonhemolytic jaundice.</p>
        <p>The syndrome is&#x000a0;classified into&#x000a0;2 types based on the level of&#x000a0;UGT activity:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Type 1:&#x000a0;</bold>Characterized by&#x000a0;severe&#x000a0;symptoms&#x000a0;due to minimal or a complete&#x000a0;absence of enzyme activity, individuals with Crigler-Najjar syndrome type 1 (CN1) experience life-threatening and severe jaundice, requiring regular phototherapy&#x000a0;for treatment. Patients with&#x000a0;this form of the disease are at very high risk of developing neurological complications, including permanent damage such as kernicterus. The only cure for&#x000a0;CN1 syndrome is a liver transplant.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Type 2:&#x000a0;</bold>This form of Crigler-Najjar syndrome is characterized by&#x000a0;milder&#x000a0;symptoms resulting from&#x000a0;reduced enzyme activity. Individuals with Crigler-Najjar syndrome type 2 (CN2) experience intermittent jaundice&#x000a0;triggered by stress and typically manage the condition through conservative measures. Permanent neurological damage is rare in CN2, and the need for a liver transplant is infrequent.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20123.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Crigler-Najjar syndrome is caused by an absence or decreased level of the UGT enzyme due to a genetic defect in the bilirubin UDP-glucuronosyltransferase family 1, polypeptide A1 (<italic toggle="yes">UGT1A1</italic>) gene.<xref ref-type="bibr" rid="article-20123.r1">[1]</xref>&#x000a0;In CN1, common mutations include deletions, alterations in intron splice donor and receptor sites, missense mutations, exon skipping, insertions, or the formation of a stop codon within the <italic toggle="yes">UGT1A1</italic> gene leading to complete deficiency of the UGT enzyme.<xref ref-type="bibr" rid="article-20123.r2">[2]</xref>&#x000a0;Conversely,&#x000a0;CN2&#x000a0;results from a point mutation in the <italic toggle="yes">UGT1A1</italic> gene, resulting in&#x000a0;reduced production of the UGT enzyme.<xref ref-type="bibr" rid="article-20123.r2">[2]</xref><xref ref-type="bibr" rid="article-20123.r3">[3]</xref></p>
      </sec>
      <sec id="article-20123.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Crigler-Najjar syndrome is an exceptionally rare disease, with an incidence rate of 0.6 to 1 in 1 million newborns worldwide.<xref ref-type="bibr" rid="article-20123.r4">[4]</xref><xref ref-type="bibr" rid="article-20123.r5">[5]</xref>&#x000a0;Despite its rarity, Crigler-Najjar syndrome requires careful medical attention and specialized care due to the severe consequences associated with elevated bilirubin levels in affected individuals.</p>
      </sec>
      <sec id="article-20123.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Bilirubin is one of the&#x000a0;byproducts produced when erythrocytes break down. Newborns are particularly vulnerable&#x000a0;to hyperbilirubinemia&#x000a0;due to their higher hemoglobin concentration at birth and impaired bilirubin excretion processes.</p>
        <p>Typically, when erythrocytes break down, bilirubin is in its unconjugated form. This unconjugated bilirubin circulates in the bloodstream and&#x000a0;enters hepatocytes, where the UGT enzyme conjugates the bilirubin, making the substance water&#x000a0;soluble. Once conjugated, the&#x000a0;bilirubin&#x000a0;is excreted into bile (see <bold>Image.</bold> Metabolic Pathway for Bilirubin in the Hepatocyte). In Crigler-Najjar syndrome, a genetic mutation reduces (in CN2) or eliminates (in CN1) this enzyme, leading to decreased or no conjugation and causing an excess&#x000a0;of unconjugated bilirubin. Due to&#x000a0;the reduced or absent conjugation and excretion, the&#x000a0;level of unconjugated bilirubin overwhelms the body's albumin. This&#x000a0;surplus&#x000a0;of indirect bilirubin accumulates in body tissues such as the skin, sclera, and brain. About 99% of bilirubin is typically bound to albumin, which cannot cross the blood-brain barrier. In contrast, free (unbound) unconjugated bilirubin easily crosses the blood-brain barrier, interacting with neural tissue.<xref ref-type="bibr" rid="article-20123.r6">[6]</xref>&#x000a0;This accumulation can lead to severe complications in individuals with Crigler-Najjar syndrome.</p>
      </sec>
      <sec id="article-20123.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Historically, hepatic histology in Crigler-Najjar syndrome was&#x000a0;believed to be normal. However, recent studies&#x000a0;have revealed&#x000a0;certain&#x000a0;pathological changes. Microscopically, bile plugs are occasionally observed within canaliculi&#x000a0;due to cholestasis. Additionally, Crigler-Najjar syndrome can&#x000a0;cause&#x000a0;hepatic parenchymal injury. A small study reported transplant patients&#x000a0;displaying significant fibrosis seen in the explants, indicating the presence of structural abnormalities in the liver tissue.<xref ref-type="bibr" rid="article-20123.r7">[7]</xref><xref ref-type="bibr" rid="article-20123.r8">[8]</xref></p>
      </sec>
      <sec id="article-20123.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>In CN1,&#x000a0;a newborn may&#x000a0;exhibit&#x000a0;jaundice, although its absence&#x000a0;does not rule out the disease. In infants born healthy, persistent jaundice&#x000a0;caused&#x000a0;by unconjugated bilirubin typically&#x000a0;appears&#x000a0;within a few days and rapidly worsens by the second week. Factors such as a family history of consanguinity, severe jaundice without&#x000a0;signs of hemolysis, relatives or family members&#x000a0;undergoing or having undergone&#x000a0;exchange transfusion therapy,&#x000a0;or a family history of liver diseases support the diagnosis. Unconjugated hyperbilirubinemia in&#x000a0;CN1 usually ranges from 20 to 25 mg/dL. However, cases with significantly elevated unconjugated bilirubin levels, reaching 50 mg/dL, have been reported.</p>
        <p>During physical&#x000a0;examination, jaundice is apparent, characterized by yellowish skin and sclera. Stool color&#x000a0;remains normal;&#x000a0;however, there is&#x000a0;reduced excretion of fecal urobilinogen due to&#x000a0;markedly&#x000a0;decreased bilirubin conjugation.&#x000a0;Besides&#x000a0;jaundice, there are no abnormal findings in both types, and no signs of liver disease are observed. Older children&#x000a0;may exhibit scratch marks on the body due to pruritus. In&#x000a0;certain&#x000a0;instances, progressive liver dysfunction&#x000a0;and&#x000a0;additional&#x000a0;toxicities can cause hepatosplenomegaly.</p>
        <p>Neurological symptoms in Crigler-Najjar syndrome arise from the toxic effects of bilirubin on the basal ganglia and brainstem nuclei for oculomotor and auditory functions. Acute bilirubin encephalopathy (ABE) initially&#x000a0;manifests&#x000a0;as sleepiness, mild to moderate hypotonia, and a high-pitched cry. Persistence of elevated bilirubin levels leads to the progression of ABE with symptoms such as fever, lethargy, poor suck, irritability, and hypertonia resulting in&#x000a0;retrocollis and opisthotonus. Advanced ABE can&#x000a0;involve&#x000a0;seizures, apnea, and a semi-comatose or comatose state. Respiratory failure or seizures can lead to fatal outcomes. Brainstem auditory-evoked responses (BAER) help detect&#x000a0;acute neurological dysfunction.<xref ref-type="bibr" rid="article-20123.r9">[9]</xref></p>
        <p>Chronic bilirubin encephalopathy (CBE),&#x000a0;also known as kernicterus, becomes apparent within the first year of life. Choreoathetoid cerebral palsy, sensorineural hearing loss, gaze abnormalities, and enamel hypoplasia characterize CBE. Generally, cognitive function remains unaffected. In instances of CBE, magnetic resonance imaging (MRI) of the brain reveals alterations in the cerebellum, hippocampus, and brainstem.<xref ref-type="bibr" rid="article-20123.r10">[10]</xref><xref ref-type="bibr" rid="article-20123.r11">[11]</xref></p>
        <p>CN2 is a milder condition characterized by fewer and less severe clinical symptoms. Patients with this syndrome may require periodic assessments to monitor bilirubin levels and liver function, aiding in the management and early detection of potential complications.</p>
      </sec>
      <sec id="article-20123.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Patients&#x000a0;suspected&#x000a0;of&#x000a0;having Crigler-Najjar syndrome should undergo serum unconjugated bilirubin level testing, with significantly higher levels seen&#x000a0;in&#x000a0;CN1 than CN2. In CN1, the unconjugated bilirubin is between 2 and 25 mg/dL, but severe cases can reach 50 mg/dL.&#x000a0;CN2 cases typically exhibit&#x000a0;levels below 20 mg/dL.</p>
        <p>Historically, collection for bile analysis involved procedures like&#x000a0;upper gastrointestinal endoscopy or duodenal catheterization, followed by high-performance liquid chromatography (HPLC). However,&#x000a0;modern diagnoses primarily rely on&#x000a0;genetic testing methods.<xref ref-type="bibr" rid="article-20123.r12">[12]</xref></p>
        <p>The administration of phenobarbital for&#x000a0;2&#x000a0;weeks has decreased serum bilirubin concentration in most patients with CN2.<xref ref-type="bibr" rid="article-20123.r13">[13]</xref>&#x000a0;Notably, CN1&#x000a0;does not respond to phenobarbital treatment.&#x000a0;</p>
        <p>Genetic analysis can be performed&#x000a0;on DNA extracted from peripheral blood leukocytes, buccal scrapings,&#x000a0;and&#x000a0;other tissues,&#x000a0;enabling&#x000a0;the identification of&#x000a0;mutations in the gene encoding the UGT enzyme. Prenatal diagnosis is possible with genetic analysis of chorionic villus samples or amniotic cells aspirated&#x000a0;from amniotic fluid aspirates. Additionally, diffusion tensor brain imaging may help&#x000a0;detect microstructural gray and white matter changes in CN1 syndrome.<xref ref-type="bibr" rid="article-20123.r14">[14]</xref>&#x000a0;Liver biopsy and histopathologic analysis can help to evaluate liver cirrhosis in established cases of hepatosplenomegaly.</p>
      </sec>
      <sec id="article-20123.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The&#x000a0;primary&#x000a0;treatment&#x000a0;goal&#x000a0;focuses&#x000a0;on&#x000a0;lowering unconjugated bilirubin levels&#x000a0;through phototherapy and plasmapheresis.&#x000a0;Although most patients survive beyond puberty without significant brain damage, they are at risk of developing kernicterus later in life.&#x000a0;Presently, liver transplantation stands as the sole curative option for CN1.<xref ref-type="bibr" rid="article-20123.r15">[15]</xref>&#x000a0;</p>
        <p>
<bold>Phototherapy</bold>
</p>
        <p>The&#x000a0;primary&#x000a0;treatment&#x000a0;approach for&#x000a0;CN1 involves intensive, often daily, phototherapy. Phototherapy is often part of the treatment of neonatal hyperbilirubinemia.<xref ref-type="bibr" rid="article-20123.r16">[16]</xref>&#x000a0;Intensive phototherapy&#x000a0;proves&#x000a0;more effective than conventional approaches as it&#x000a0;leads to a quicker response, shortens the treatment duration, and minimizes late complications.<xref ref-type="bibr" rid="article-20123.r17">[17]</xref>&#x000a0;Phototherapy is less effective in older children and adults due to thicker skin, increased skin pigmentation, and&#x000a0;smaller body surface area in proportion to body mass.<xref ref-type="bibr" rid="article-20123.r15">[15]</xref></p>
        <p>
<bold>Plasmapheresis</bold>
</p>
        <p>Plasmapheresis is the most effective&#x000a0;method&#x000a0;for removing excess unconjugated bilirubin from the blood during severe hyperbilirubinemia crisis.&#x000a0;This process&#x000a0;involves extracting blood from the patient, separating blood cells from plasma, and replacing the plasma with donor plasma. The patient's blood is then transfused back after this exchange. Bilirubin tightly&#x000a0;binds to albumin; therefore,&#x000a0;removing&#x000a0;albumin during&#x000a0;plasmapheresis&#x000a0;effectively reduces&#x000a0;bilirubin levels in the bloodstream. Plasmapheresis serves as a targeted approach to eliminating unwanted substances from the blood.&#x000a0;&#x000a0;</p>
        <p>
<bold>Orlistat</bold>
</p>
        <p>Orlistat, a&#x000a0;lipase inhibitor, demonstrates enhanced efficiency&#x000a0;when used alongside&#x000a0;calcium phosphate.&#x000a0;The theory behind its mechanism suggests that it&#x000a0;captures unconjugated intestinal bilirubin and&#x000a0;aids&#x000a0;in its excretion, correlating with the amount of fat&#x000a0;expelled in stools.<xref ref-type="bibr" rid="article-20123.r18">[18]</xref></p>
        <p>
<bold>Calcium Phosphate Supplementation</bold>
</p>
        <p>A randomized controlled study of patients with CN1, who have undergone phototherapy and were supplemented with calcium phosphate, demonstrated an 18% reduction in serum bilirubin levels. This indicates that calcium phosphate may trap photoproducts excreted in the bile.<xref ref-type="bibr" rid="article-20123.r19">[19]</xref>&#x000a0;Supporting this, animal studies&#x000a0;with rats have shown decreased serum bilirubin concentrations&#x000a0;following oral calcium phosphate supplementation, likely&#x000a0;due to the&#x000a0;trapping of unconjugated bilirubin in the gut.<xref ref-type="bibr" rid="article-20123.r20">[20]</xref></p>
        <p>
<bold>Liver Transplantation</bold>
</p>
        <p>Liver transplantation stands as the sole&#x000a0;therapeutic and definitive treatment method for CN1. The transplanted liver&#x000a0;possesses&#x000a0;a healthy UGT enzyme, enabling effective bilirubin conjugation and rapidly&#x000a0;lowering serum bilirubin levels. Prophylactic liver transplantation is&#x000a0;highly recommended&#x000a0;to prevent kernicterus, as once&#x000a0;this condition develops, it may not be&#x000a0;reversible.<xref ref-type="bibr" rid="article-20123.r21">[21]</xref></p>
        <p>
<bold>Hepatocyte Transplantation</bold>
</p>
        <p>Hepatocyte transplantation is a promising alternative to liver transplantation.&#x000a0;During this procedure,&#x000a0;healthy hepatocytes are infused into the portal vein or the peritoneal space. This method&#x000a0;offers a temporary reduction of&#x000a0;serum bilirubin levels, with published reports&#x000a0;showing a 50% reduction in bilirubin levels.<xref ref-type="bibr" rid="article-20123.r22">[22]</xref><xref ref-type="bibr" rid="article-20123.r23">[23]</xref></p>
        <p>
<bold>Gene Therapy</bold>
</p>
        <p>The potential cure for the genetic defect lies in introducing a normal <italic toggle="yes">UGT1A1</italic> gene, achieved through ex vivo gene transduction, where the gene is&#x000a0;introduced into cultured hepatocytes or&#x000a0;vector-mediated gene delivery methods. Adenovirus is the most effective vector for transferring genes to liver cells.<xref ref-type="bibr" rid="article-20123.r4">[4]</xref>&#x000a0;Currently, plans for conducting clinical trials in humans are underway, marking significant progress in pursuing a cure.</p>
        <p>
<bold>Inhibition of Bilirubin Production</bold>
</p>
        <p>A single dose of heme oxygenase inhibitors, like tin-protoporphyrin or tin-mesoporphyrin, administered to neonates has demonstrated a 76% decrease in bilirubin&#x000a0;levels, eliminating the&#x000a0;necessity&#x000a0;for phototherapy.<xref ref-type="bibr" rid="article-20123.r24">[24]</xref><xref ref-type="bibr" rid="article-20123.r25">[25]</xref>&#x000a0;However, in adults, this effect is short-lived and therefore reserved for acute emergencies.</p>
        <p>
<bold>Phenobarbitol</bold>
</p>
        <p>Patients with Crigler-Najjar syndrome usually do not require treatment with phenobarbital. However, patients&#x000a0;experiencing jaundice&#x000a0;that&#x000a0;impacts their quality of life may receive phenobarbital therapy, which works by inducing the&#x000a0;remaining UGT activity. Notably, phenobarbitol has no role in CN1, but it can reduce the serum bilirubin level by 25% in patients with CN2.<xref ref-type="bibr" rid="article-20123.r13">[13]</xref>&#x000a0;There have been documented cases&#x000a0;where pregnant women with&#x000a0;CN2&#x000a0;were&#x000a0;successfully treated with phenobarbital during pregnancy.<xref ref-type="bibr" rid="article-20123.r26">[26]</xref><xref ref-type="bibr" rid="article-20123.r27">[27]</xref></p>
      </sec>
      <sec id="article-20123.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Distinguishing Crigler-Najjar syndrome from other causes&#x000a0;of unconjugated hyperbilirubinemia&#x000a0;relies&#x000a0;on&#x000a0;evaluating the bilirubin levels and the duration of hyperbilirubinemia. Additionally, classification is based on&#x000a0;underlying causes and specific conditions.</p>
        <p>
<bold>Increased Production</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hemolysis:&#x000a0;Conditions like&#x000a0;sickle cell disease, hereditary spherocytosis, and Rh isoimmunization can lead to hemolysis, where the bilirubin level&#x000a0;typically remains below&#x000a0;6 to 8 mg/dL in exclusive hemolysis cases in newborns. Rh isoimmunization,&#x000a0; incompatible fetal and maternal red cells, can cause pronounced jaundice but is always associated with signs of active hemolysis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ineffective erythropoiesis: Diseases related to ineffective erythropoiesis, such as thalassemia, pernicious anemia, iron deficiency anemia, and lead poisoning, can result in a marked increase in bilirubin levels.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Gastrointestinal (GI) bleeding and hematoma: GI bleeding and hematomas contribute to hyperbilirubinemia. One case report with hematochezia and jaundice reported polyp formation was responsible for rectal bleeding related to biliary abnormalities.<xref ref-type="bibr" rid="article-20123.r28">[28]</xref> Conditions like hemobilia, where GI bleeding leads to resorption of blood and an increase in unconjugated bilirubin concentration, can cause jaundice.<xref ref-type="bibr" rid="article-20123.r29">[29]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Decreased Clearance</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Liver diseases:&#x000a0;Any&#x000a0;liver disease affecting the conjugation&#x000a0;and efficient excretion of bilirubin can lead to jaundice.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Drug-induced: Liver injury caused by drugs such as&#x000a0;amoxicillin, cefazolin, nitrofurantoin, chloramphenicol, and isoniazid can impair the liver's conjugating capacity, resulting in hyperbilirubinemia.<xref ref-type="bibr" rid="article-20123.r30">[30]</xref><xref ref-type="bibr" rid="article-20123.r31">[31]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Genetic Conditions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Gilbert syndrome: This common inherited hyperbilirubinemia affects the <italic toggle="yes">UGT1A1</italic> gene's promoter region, reducing normal protein production.&#x000a0;As the UGT enzyme deficiency is not severe, Gilbert syndrome has benign manifestations, distinguishing it from CN1.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lucey-Driscoll syndrome:&#x000a0;Also known as transient familial hyperbilirubinemia, it is caused by compounds in the mother's and baby's blood that block the bilirubin breakdown.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Neonatal jaundice and prematurity: Physiologic jaundice in newborns can result from various factors like liver dysfunction, infection, hypothyroidism, and metabolic disorders. Premature infants often have higher bilirubin levels due to immaturity. Physiologic jaundice usually resolves within the first&#x000a0;10 days of life.</p>
          </list-item>
        </list>
        <p>
<bold>Special Cases</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Breast milk jaundice: Some breastfeeding neonates&#x000a0;experience elevated bilirubin within&#x000a0;2 weeks of birth,&#x000a0;lasting&#x000a0;3 to 12 weeks, often longer than physiologic jaundice.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Rotor syndrome and Dubin-Johnson syndrome: Rare inherited disorders causing jaundice with high levels of conjugated bilirubin. Rotor syndrome results&#x000a0;from alterations in&#x000a0;2 genes,&#x000a0;<italic toggle="yes">SLCO1B1</italic>&#x000a0;and&#x000a0;<italic toggle="yes">SLCO1B3</italic>, while Dubin-Johnson syndrome results&#x000a0;from <italic toggle="yes">ABCC2</italic>&#x000a0;gene mutations.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20123.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>CN1&#x000a0;has a poor prognosis, often necessitating emergent intervention during hyperbilirubinemia crises. Once kernicterus develops, this syndrome tends to be irreversible. In contrast, CN2,&#x000a0;due to residual UGT enzyme activity,&#x000a0;presents with mild symptoms or can even be asymptomatic.&#x000a0;Studies report varying incidences of permanent neurological impairment in patients with CN1, ranging up to 30% of cases.<xref ref-type="bibr" rid="article-20123.r15">[15]</xref><xref ref-type="bibr" rid="article-20123.r32">[32]</xref><xref ref-type="bibr" rid="article-20123.r33">[33]</xref></p>
      </sec>
      <sec id="article-20123.s12" sec-type="Complications">
        <title>Complications</title>
        <p>An outline of potential complications for Crigler-Najjar syndrome are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Kernicterus: Unconjugated bilirubin, being fat-soluble, can&#x000a0;penetrate&#x000a0;cell membranes. At high serum levels,&#x000a0;typically above 25 mg/dL, unconjugated bilirubin can cross the blood-brain barrier, causing neurotoxicity. While more commonly seen in patients with CN1, patients with CN2 are&#x000a0;also at risk, especially in cases where&#x000a0;serum bilirubin levels may rise to 40 mg/dL. Commonly affected areas of the brain include the hippocampus, geniculate bodies, basal ganglia, and nerve nuclei.<xref ref-type="bibr" rid="article-20123.r34">[34]</xref>&#x000a0;Early diagnosis and treatment are crucial to prevent kernicterus.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chronic jaundice: Persistent disease and&#x000a0;delayed diagnosis lead to chronic jaundice. Bilirubin levels&#x000a0;progressively increase due to limited excretion, leading to widespread deposition throughout the body at later stages.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cholelithiasis: Increased unconjugated bilirubin concentration can lead to gallstone formation, usually appearing later in life due to the gradual accumulation of bilirubin.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Liver cirrhosis: Liver cirrhosis develops over a&#x000a0;prolonged&#x000a0;period. Most children born with Crigler-Najjar&#x000a0;syndrome have healthy livers initially.&#x000a0;The exact mechanism of liver cirrhosis remains unknown. However, it may result from chronic biliary obstruction secondary to cholelithiasis, toxicity from drugs primarily metabolized in the liver, toxicity from phototherapy, and heme degradation products.<xref ref-type="bibr" rid="article-20123.r35">[35]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20123.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>Consultations for Crigler-Najjar syndrome typically involve a multidisciplinary team of healthcare professionals, including neonatology, pediatric gastroenterology and hepatology, pediatric genetics, genetic counselor, neurologist, and nutritionist or dietitian. The patient's pediatrician or neonatologist is crucial for the initial diagnosis and monitoring of the child's growth and overall health.</p>
        <p>Referral to a pediatric gastroenterologist or hepatologist may be necessary for specialized care for liver diseases, including monitoring for liver-related complications. They also play a crucial role in assessing the eligibility for liver transplantation, coordinating the transplant evaluation process, and providing post-transplant care, ensuring comprehensive management of liver-related challenges in Crigler-Najjar syndrome patients.</p>
        <p>The care team may also comprise a genetic counselor to help the family understand the genetic implications of the syndrome, provide information about inheritance patterns, and discuss the risk of passing the condition to future generations. If there are neurological complications or concerns, a neurologist may also be necessary. Nutritionists and dietitians can assist in developing specialized diet plans to manage the condtion,&#x000a0;ensuring adequate nutrition while minimizing the risk of bilirubin buildup.</p>
      </sec>
      <sec id="article-20123.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Crigler-Najjar syndrome leads to&#x000a0;an accumulation of bilirubin in the blood due to an abnormal gene inherited within families. The disease severity&#x000a0;varies between&#x000a0;its&#x000a0;2 types, making differentiation crucial for appropriate interventions. Screening&#x000a0;close&#x000a0;relatives&#x000a0;is advisable. Tailored patient education, adapted to the parents' understanding, is essential. Detailed information about signs and symptoms&#x000a0;empowers&#x000a0;parents to facilitate early&#x000a0;diagnosis and treatment, preventing complications and&#x000a0;enhancing&#x000a0;outcomes. Additionally, educating parents about the&#x000a0;advantages and disadvantages of different tests and treatments is vital for making well-informed decisions.</p>
      </sec>
      <sec id="article-20123.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>A collaborative interprofessional team, utilizing an evidence-based approach for initial diagnosis and&#x000a0;subsequent monitoring, is crucial in&#x000a0;Crigler-Najjar syndrome.&#x000a0;Early diagnosis and timely therapeutic&#x000a0;interventions,&#x000a0;facilitated by this team, can significantly improve outcomes by reducing the duration of treatments and preventing complications. Neonatologists, drawing on their clinical expertise, play a pivotal role in&#x000a0;diagnosing the condition. Pediatric gastroenterologists, medical geneticists, and histopathologists&#x000a0;further confirm the diagnosis.</p>
        <p>In cases complicated by kernicterus or early ABE, pediatric neurologists are instrumental in managing severity and&#x000a0;communicating prognosis details to parents. Pediatric surgeons contribute to curative treatment by liver transplantation. Hospitalized patients' outcomes are influenced by hospital protocols and the quality of care. While patients with&#x000a0;CN1 often await liver transplantation, effective management in a hospital setting is essential to prevent kernicterus.<xref ref-type="bibr" rid="article-20123.r33">[33]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-20123.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20123&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20123">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/crigler-najjar-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=20123">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20123/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20123">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-20123.s17">
        <fig id="article-20123.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Metabolic Pathway for Bilirubin in the Hepatocyte. Bilirubin-G corresponds to bilirubin glucuronate; the donor is uridine diphosphate glucuronic acid (UDP-GA). This is catalyzed by the enzyme uridine diphosphate-glucuronyltransferase (UGT1A1). Gilbert and Crigler-Najjar syndrome is associated with decreases in UGT1A1 activity. Glutathione-S-transferase (GST) is a carrier protein that assists bilirubin uptake into the cytosol and may be implicated in Rotor syndrome. Contributed by R Kabir, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Kabir_Rotor__Syndrome" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-20123.s18">
        <title>References</title>
        <ref id="article-20123.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gailite</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Valenzuela-Palomo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sanoguera-Miralles</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rots</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kreile</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Velasco</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title><italic>UGT1A1</italic> Variants c.864+5G&#x0003e;T and c.996+2_996+5del of a Crigler-Najjar Patient Induce Aberrant Splicing in Minigene Assays.</article-title>
            <source>Front Genet</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>169</fpage>
            <pub-id pub-id-type="pmid">32211025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erps</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Ritter</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Hersh</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Blossom</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Owens</surname>
                <given-names>IS</given-names>
              </name>
            </person-group>
            <article-title>Identification of two single base substitutions in the UGT1 gene locus which abolish bilirubin uridine diphosphate glucuronosyltransferase activity in vitro.</article-title>
            <source>J Clin Invest</source>
            <year>1994</year>
            <month>Feb</month>
            <volume>93</volume>
            <issue>2</issue>
            <fpage>564</fpage>
            <page-range>564-70</page-range>
            <pub-id pub-id-type="pmid">7906695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kadakol</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sappal</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Lowenheim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chowdhury</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chowdhury</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Santra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arias</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Chowdhury</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Chowdhury</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <article-title>Interaction of coding region mutations and the Gilbert-type promoter abnormality of the UGT1A1 gene causes moderate degrees of unconjugated hyperbilirubinaemia and may lead to neonatal kernicterus.</article-title>
            <source>J Med Genet</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>244</fpage>
            <page-range>244-9</page-range>
            <pub-id pub-id-type="pmid">11370628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Collaud</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bortolussi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Guianvarc'h</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Aronson</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Bordet</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Veron</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Charles</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vidal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sola</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Rundwasser</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dufour</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Lacoste</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Luc</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wittenberghe</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Le Bec</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bosma</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Muro</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Ronzitti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hebben</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mingozzi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome.</article-title>
            <source>Mol Ther Methods Clin Dev</source>
            <year>2019</year>
            <month>Mar</month>
            <day>15</day>
            <volume>12</volume>
            <fpage>157</fpage>
            <page-range>157-174</page-range>
            <pub-id pub-id-type="pmid">30705921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ebrahimi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rahim</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Crigler-Najjar Syndrome: Current Perspectives and the Application of Clinical Genetics.</article-title>
            <source>Endocr Metab Immune Disord Drug Targets</source>
            <year>2018</year>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>201</fpage>
            <page-range>201-211</page-range>
            <pub-id pub-id-type="pmid">29237388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strauss</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Ahlfors</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Soltys</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mazareigos</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bowser</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Squires</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>McKiernan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brigatti</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Puffenberger</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Vreman</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Crigler-Najjar Syndrome Type 1: Pathophysiology, Natural History, and Therapeutic Frontier.</article-title>
            <source>Hepatology</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>1923</fpage>
            <page-range>1923-1939</page-range>
            <pub-id pub-id-type="pmid">31553814</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitchell</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ranganathan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McKiernan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Squires</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Strauss</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Soltys</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mazariegos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Squires</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Hepatic Parenchymal Injury in Crigler-Najjar Type I.</article-title>
            <source>J Pediatr Gastroenterol Nutr</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>66</volume>
            <issue>4</issue>
            <fpage>588</fpage>
            <page-range>588-594</page-range>
            <pub-id pub-id-type="pmid">29176474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fata</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Gillis</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Pacheco</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Liver Fibrosis Associated With Crigler-Najjar Syndrome in a Compound Heterozygote: A Case Report.</article-title>
            <source>Pediatr Dev Pathol</source>
            <year>2017</year>
            <season>Nov-Dec</season>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>522</fpage>
            <page-range>522-525</page-range>
            <pub-id pub-id-type="pmid">28590786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vohr</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Karp</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>O'Dea</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Darrow</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Coll</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Lester</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cashore</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Behavioral changes correlated with brain-stem auditory evoked responses in term infants with moderate hyperbilirubinemia.</article-title>
            <source>J Pediatr</source>
            <year>1990</year>
            <month>Aug</month>
            <volume>117</volume>
            <issue>2 Pt 1</issue>
            <fpage>288</fpage>
            <page-range>288-91</page-range>
            <pub-id pub-id-type="pmid">2380830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wisnowski</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Panigrahy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Painter</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Watchko</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Magnetic Resonance Imaging Abnormalities in Advanced Acute Bilirubin Encephalopathy Highlight Dentato-Thalamo-Cortical Pathways.</article-title>
            <source>J Pediatr</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>174</volume>
            <fpage>260</fpage>
            <page-range>260-3</page-range>
            <pub-id pub-id-type="pmid">27113379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wisnowski</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Panigrahy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Painter</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Watchko</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Magnetic resonance imaging of bilirubin encephalopathy: current limitations and future promise.</article-title>
            <source>Semin Perinatol</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>38</volume>
            <issue>7</issue>
            <fpage>422</fpage>
            <page-range>422-8</page-range>
            <pub-id pub-id-type="pmid">25267277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tcaciuc</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Podurean</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tcaciuc</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Management of Crigler-Najjar syndrome.</article-title>
            <source>Med Pharm Rep</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>94</volume>
            <issue>Suppl No 1</issue>
            <fpage>S64</fpage>
            <page-range>S64-S67</page-range>
            <pub-id pub-id-type="pmid">34527915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arias</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Gartner</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ezzer</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Levi</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Chronic nonhemolytic unconjugated hyperbilirubinemia with glucuronyl transferase deficiency. Clinical, biochemical, pharmacologic and genetic evidence for heterogeneity.</article-title>
            <source>Am J Med</source>
            <year>1969</year>
            <month>Sep</month>
            <volume>47</volume>
            <issue>3</issue>
            <fpage>395</fpage>
            <page-range>395-409</page-range>
            <pub-id pub-id-type="pmid">4897277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Razek</surname>
                <given-names>AAKA</given-names>
              </name>
              <name>
                <surname>Taman</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>El Regal</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Megahed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elzeny</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>El Tantawi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Diffusion Tensor Imaging of Microstructural Changes in the Gray and White Matter in Patients With Crigler-Najjar Syndrome Type I.</article-title>
            <source>J Comput Assist Tomogr</source>
            <year>2020</year>
            <season>May/Jun</season>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>393</fpage>
            <page-range>393-398</page-range>
            <pub-id pub-id-type="pmid">32217895</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Veere</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Sinaasappel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McDonagh</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Labrune</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Odi&#x000e8;vre</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fevery</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Otte</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>McClean</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>B&#x000fc;rk</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Masakowski</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sperl</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mowat</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Vergani</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Shepherd</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>Current therapy for Crigler-Najjar syndrome type 1: report of a world registry.</article-title>
            <source>Hepatology</source>
            <year>1996</year>
            <month>Aug</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>311</fpage>
            <page-range>311-5</page-range>
            <pub-id pub-id-type="pmid">8690398</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lund</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Influence of phototherapy on the biliary bilirubin excretion pattern in newborn infants with hyperbilirubinemia.</article-title>
            <source>J Pediatr</source>
            <year>1974</year>
            <month>Aug</month>
            <volume>85</volume>
            <issue>2</issue>
            <fpage>262</fpage>
            <page-range>262-7</page-range>
            <pub-id pub-id-type="pmid">4842799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>XR</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Effect and safety of intensive phototherapy in treatment of neonatal hyperbilirubinemia].</article-title>
            <source>Zhongguo Dang Dai Er Ke Za Zhi</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>195</fpage>
            <page-range>195-200</page-range>
            <pub-id pub-id-type="pmid">26975813</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishioka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hafkamp</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Havinga</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>vn Lierop</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Velvis</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Verkade</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Orlistat treatment increases fecal bilirubin excretion and decreases plasma bilirubin concentrations in hyperbilirubinemic Gunn rats.</article-title>
            <source>J Pediatr</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>143</volume>
            <issue>3</issue>
            <fpage>327</fpage>
            <page-range>327-34</page-range>
            <pub-id pub-id-type="pmid">14517515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van der Veere</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Sinaasappel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van der Meer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Van der Sijs</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rammeloo</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Goyens</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Van Nieuwkerk</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Oude Elferink</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Oral calcium phosphate: a new therapy for Crigler-Najjar disease?</article-title>
            <source>Gastroenterology</source>
            <year>1997</year>
            <month>Feb</month>
            <volume>112</volume>
            <issue>2</issue>
            <fpage>455</fpage>
            <page-range>455-62</page-range>
            <pub-id pub-id-type="pmid">9024299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Der Veere</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Schoemaker</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bakker</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Van Der Meer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Elferink</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Influence of dietary calcium phosphate on the disposition of bilirubin in rats with unconjugated hyperbilirubinemia.</article-title>
            <source>Hepatology</source>
            <year>1996</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>620</fpage>
            <page-range>620-6</page-range>
            <pub-id pub-id-type="pmid">8781334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sokal</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Hermans</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Reding</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de Ville de Goyet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Buts</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Otte</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Orthotopic liver transplantation for Crigler-Najjar type I disease in six children.</article-title>
            <source>Transplantation</source>
            <year>1995</year>
            <month>Nov</month>
            <day>27</day>
            <volume>60</volume>
            <issue>10</issue>
            <fpage>1095</fpage>
            <page-range>1095-8</page-range>
            <pub-id pub-id-type="pmid">7482714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ambrosino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Varotto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Strom</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Guariso</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Franchin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Miotto</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Caenazzo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Basso</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carraro</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Valente</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>D'Amico</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zancan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>D'Antiga</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Isolated hepatocyte transplantation for Crigler-Najjar syndrome type 1.</article-title>
            <source>Cell Transplant</source>
            <year>2005</year>
            <volume>14</volume>
            <issue>2-3</issue>
            <fpage>151</fpage>
            <page-range>151-7</page-range>
            <pub-id pub-id-type="pmid">15881424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fox</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Chowdhury</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Goertzen</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Chowdhury</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Warkentin</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>Dorko</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sauter</surname>
                <given-names>BV</given-names>
              </name>
              <name>
                <surname>Strom</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation.</article-title>
            <source>N Engl J Med</source>
            <year>1998</year>
            <month>May</month>
            <day>14</day>
            <volume>338</volume>
            <issue>20</issue>
            <fpage>1422</fpage>
            <page-range>1422-6</page-range>
            <pub-id pub-id-type="pmid">9580649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valaes</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Petmezaki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Henschke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Drummond</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Kappas</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Control of jaundice in preterm newborns by an inhibitor of bilirubin production: studies with tin-mesoporphyrin.</article-title>
            <source>Pediatrics</source>
            <year>1994</year>
            <month>Jan</month>
            <volume>93</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-11</page-range>
            <pub-id pub-id-type="pmid">8265301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kappas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drummond</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Henschke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Valaes</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Direct comparison of Sn-mesoporphyrin, an inhibitor of bilirubin production, and phototherapy in controlling hyperbilirubinemia in term and near-term newborns.</article-title>
            <source>Pediatrics</source>
            <year>1995</year>
            <month>Apr</month>
            <volume>95</volume>
            <issue>4</issue>
            <fpage>468</fpage>
            <page-range>468-74</page-range>
            <pub-id pub-id-type="pmid">7700742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holstein</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bryan</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Three consecutive pregnancies in a woman with Crigler-Najjar syndrome type II with good maternal and neonatal outcomes.</article-title>
            <source>Dig Liver Dis</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>43</volume>
            <issue>2</issue>
            <fpage>170</fpage>
            <pub-id pub-id-type="pmid">20843754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Passuello</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Puhl</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Wirth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Steiner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Skala</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Koelbl</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kohlschmidt</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Pregnancy outcome in maternal Crigler-Najjar syndrome type II: a case report and systematic review of the literature.</article-title>
            <source>Fetal Diagn Ther</source>
            <year>2009</year>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>121</fpage>
            <page-range>121-6</page-range>
            <pub-id pub-id-type="pmid">19752526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>He</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Jaundice and rectal bleeding in a young man.</article-title>
            <source>Gut</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>60</volume>
            <issue>7</issue>
            <fpage>892</fpage>
            <page-range>892, 936</page-range>
            <pub-id pub-id-type="pmid">20542867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berry</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Kardashian</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>LaRusso</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Tabibian</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Hemobilia: Etiology, diagnosis, and treatment<sup>&#x02606;</sup>.</article-title>
            <source>Liver Res</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>200</fpage>
            <page-range>200-208</page-range>
            <pub-id pub-id-type="pmid">31308984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>deLemos</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Ghabril</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rockey</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barnhart</surname>
                <given-names>HX</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kleiner</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Bonkovsky</surname>
                <given-names>HL</given-names>
              </name>
              <collab>Drug-Induced Liver Injury Network (DILIN)</collab>
            </person-group>
            <article-title>Amoxicillin-Clavulanate-Induced Liver Injury.</article-title>
            <source>Dig Dis Sci</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>61</volume>
            <issue>8</issue>
            <fpage>2406</fpage>
            <page-range>2406-2416</page-range>
            <pub-id pub-id-type="pmid">27003146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bj&#x000f6;rnsson</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced liver injury due to antibiotics.</article-title>
            <source>Scand J Gastroenterol</source>
            <year>2017</year>
            <season>Jun-Jul</season>
            <volume>52</volume>
            <issue>6-7</issue>
            <fpage>617</fpage>
            <page-range>617-623</page-range>
            <pub-id pub-id-type="pmid">28276834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suresh</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lucey</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Lack of deafness in Crigler-Najjar syndrome type 1: a patient survey.</article-title>
            <source>Pediatrics</source>
            <year>1997</year>
            <month>Nov</month>
            <volume>100</volume>
            <issue>5</issue>
            <fpage>E9</fpage>
            <pub-id pub-id-type="pmid">9347003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strauss</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Vreman</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Puffenberger</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Hart</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Morton</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Management of hyperbilirubinemia and prevention of kernicterus in 20 patients with Crigler-Najjar disease.</article-title>
            <source>Eur J Pediatr</source>
            <year>2006</year>
            <month>May</month>
            <volume>165</volume>
            <issue>5</issue>
            <fpage>306</fpage>
            <page-range>306-19</page-range>
            <pub-id pub-id-type="pmid">16435131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamza</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Kernicterus.</article-title>
            <source>Autops Case Rep</source>
            <year>2019</year>
            <season>Jan-Mar</season>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>e2018057</fpage>
            <pub-id pub-id-type="pmid">30863731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20123.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bar&#x00131;&#x0015f;</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>&#x000d6;z&#x000e7;ay</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Usta</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>&#x000d6;zg&#x000fc;n</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Liver Cirrhosis in a Patient with Crigler Najjar Syndrome.</article-title>
            <source>Fetal Pediatr Pathol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>301</fpage>
            <page-range>301-306</page-range>
            <pub-id pub-id-type="pmid">30260719</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
